FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Allan Wissner

Research Profile

Chemicals & Drugs

Concepts & Ideas

Phenomena

Phosphorylation

Physiology

Cell Divisions

Living Beings

Anatomy

Tumor Cells, Cultured

Procedures

Drug Screening Assays, Antitumor

Co-author Network

Publications

TOP 3
Thomas Nittoli; Russell G Dushin; Charles Ingalls; Katherine Cheung; M Brawner Floyd; Heidi Fraser; Andrea Olland; Yongbo Hu; George Grosu; Xin Han; Kim Arndt; Bing Guo; Allan Wissner
The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1).
Kyung-Hee Kim; Allan Wissner; Middleton B Floyd; Heidi L Fraser; Yanong D Wang; Russell G Dushin; Yongbo Hu; Andrea Olland; Bing Guo; Kim Arndt
Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
Russell G Dushin; Thomas Nittoli; Charles Ingalls; Diane H Boschelli; Derek C Cole; Allan Wissner; Julie Lee; Xiaoke Yang; Paul Morgan; Agnes Brennan; Divya Chaudhary
Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Allan Wissner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Thomas Nittoli; Russell G Dushin; Charles Ingalls; Katherine Cheung; M Brawner Floyd; Heidi Fraser; Andrea Olland; Yongbo Hu; George Grosu; Xin Han; Kim Arndt; Bing Guo; Allan Wissner
The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1).
European journal of medicinal chemistry 2010;45(4):1379-86.
2009: Kyung-Hee Kim; Allan Wissner; Middleton B Floyd; Heidi L Fraser; Yanong D Wang; Russell G Dushin; Yongbo Hu; Andrea Olland; Bing Guo; Kim Arndt
Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
Bioorganic & medicinal chemistry letters 2009;19(17):5225-8.
2009: Russell G Dushin; Thomas Nittoli; Charles Ingalls; Diane H Boschelli; Derek C Cole; Allan Wissner; Julie Lee; Xiaoke Yang; Paul Morgan; Agnes Brennan; Divya Chaudhary
Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.
Bioorganic & medicinal chemistry letters 2009;19(9):2461-3.
2009: Jack A Bikker; Natasja Brooijmans; Allan Wissner; Tarek S Mansour
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
Journal of medicinal chemistry 2009;52(6):1493-509.
2008: Derek C Cole; Magda Asselin; Agnes Brennan; Robert Czerwinski; John W Ellingboe; Lori Fitz; Rita Greco; Xinyi Huang; Diane Joseph-McCarthy; Michael F Kelly; Matthew Kirisits; Julie Lee; Yuanhong Li; Paul Morgan; Joseph R Stock; Desirée H H Tsao; Allan Wissner; Xiaoke Yang; Divya Chaudhary
Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
Journal of medicinal chemistry 2008;51(19):5958-63.
2008: Allan Wissner; Tarek S Mansour
The development of HKI-272 and related compounds for the treatment of cancer.
Archiv der Pharmazie 2008;341(8):465-77.
2007: Allan Wissner; Heidi L Fraser; Charles L Ingalls; Russell G Dushin; M Brawner Floyd; Kinwang Cheung; Thomas Nittoli; Malini R Ravi; Xingzhi Tan; Frank Loganzo
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Bioorganic & medicinal chemistry 2007;15(11):3635-48.
2005: Allan Wissner; M Brawner Floyd; Bernard D Johnson; Heidi Fraser; Charles Ingalls; Thomas Nittoli; Russell G Dushin; Carolyn Discafani; Ramaswamy Nilakantan; Joseph Marini; Malini Ravi; Kinwang Cheung; Xingzhi Tan; Sylvia Musto; Tami Annable; Marshall M Siegel; Frank Loganzo
2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Journal of medicinal chemistry 2005;48(24):7560-81.
2005: Eunice L Kwak; Raffaella Sordella; Daphne W Bell; Nadia Godin-Heymann; Ross A Okimoto; Brian W Brannigan; Patricia Neal; David R Driscoll; Panos Fidias; Thomas J Lynch; Sridhar K Rabindran; John P McGinnis; Allan Wissner; Sreenath V Sharma; Kurt J Isselbacher; Jeffrey Settleman; Daniel A Haber
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(21):7665-70.
2005: Hwei-Ru Tsou; Elsebe G Overbeek-Klumpers; William A Hallett; Marvin F Reich; M Brawner Floyd; Bernard D Johnson; Ronald S Michalak; Ramaswamy Nilakantan; Carolyn Discafani; Jennifer M Golas; Sridhar K Rabindran; Ru Shen; Xiaoqing Shi; Yu-Fen Wang; Janis Upeslacis; Allan Wissner
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
Journal of medicinal chemistry 2005;48(4):1107-31.
2004: Sridhar K Rabindran; Carolyn Discafani; Edward C Rosfjord; Michelle Baxter; M Brawner Floyd; Jennifer M Golas; William A Hallett; Bernard D Johnson; Ramaswamy Nilakantan; Elsebe Overbeek; Marvin F Reich; Ru Shen; Xiaoqing Shi; Hwei-Ru Tsou; Yu-Fen Wang; Allan Wissner
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
Cancer research 2004;64(11):3958-65.
2004: Allan Wissner; Philip R Hamann; Ramaswamy Nilakantan; Lee M Greenberger; Fei Ye; Timothy A Rapuano; Frank Loganzo
Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.
Bioorganic & medicinal chemistry letters 2004;14(6):1411-6.
2003: Dan Berger; Minu Dutia; Dennis Powell; Biqi Wu; Allan Wissner; Diane H Boschelli; M Brawner Floyd; Nan Zhang; Nancy Torres; Jeremy Levin; Xuemei Du; Donald Wojciechowicz; Carolyn Discafani; Constance Kohler; Steven C Kim; Larry Feldberg; Karen Collins; Robert Mallon
Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade.
Bioorganic & medicinal chemistry letters 2003;13(18):3031-4.
2003: Allan Wissner; Elsebe Overbeek; Marvin F Reich; M Brawner Floyd; Bernard D Johnson; Nellie Mamuya; Edward C Rosfjord; Carolyn Discafani; Rachel Davis; Xiaoqing Shi; Sridhar K Rabindran; Brian C Gruber; Fei Ye; William A Hallett; Ramaswamy Nilakantan; Ru Shen; Yu-Fen Wang; Lee M Greenberger; Hwei-Ru Tsou
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
Journal of medicinal chemistry 2003;46(1):49-63.
2002: Dan Berger; Minu Dutia; Dennis Powell; Allan Wissner; Frenel DeMorin; Yuri Raifeld; Jennifer Weber; Frank Boschelli
Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Bioorganic & medicinal chemistry letters 2002;12(20):2989-92.
2002: Allan Wissner; M Brawner Brawner Floyd; Sridhar K Rabindran; Ramaswamy Nilakantan; Lee M Greenberger; Ru Shen; Yu-Fen Wang; Hwei-Ru Tsou
Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.
Bioorganic & medicinal chemistry letters 2002;12(20):2893-7.
2002: Dan Berger; Minu Dutia; Dennis Powell; Biqi Wu; Allan Wissner; Frenel DeMorin; Jennifer Weber; Frank Boschelli
8-Anilinoimidazo[4,5-g]quinoline-7-carbonitriles as Src kinase inhibitors.
Bioorganic & medicinal chemistry letters 2002;12(19):2761-5.
2002: Nan Zhang; Biqi Wu; Allan Wissner; Dennis W Powell; Sridhar K Rabindran; Constance Kohler; Frank Boschelli
4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors.
Bioorganic & medicinal chemistry letters 2002;12(3):423-5.
2001: Hwei-Ru Tsou; Nellie Mamuya; Bernard D Johnson; Marvin F Reich; Brian C Gruber; Fei Ye; Ramaswamy Nilakantan; Ru Shen; Carolyn Discafani; R DeBlanc; R Davis; F E Koehn; Lee M Greenberger; Yu-Fen Wang; Allan Wissner
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
Journal of medicinal chemistry 2001;44(17):2719-34.
2001: Nan Zhang; Biqi Wu; N Eudy; Yihan Wang; Fei Ye; Dennis Powell; Allan Wissner; Larry Feldberg; Steven C Kim; Robert Mallon; ED Kovacs; L Toral-Barza; C A Kohler
MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines.
Bioorganic & medicinal chemistry letters 2001;11(11):1407-10.
2001: Diane H Boschelli; Yanong D Wang; Fei Ye; Biqi Wu; Nan Zhang; Minu Dutia; Dennis W Powell; Allan Wissner; Kim Arndt; JM Weber; Frank Boschelli
Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles.
Journal of medicinal chemistry 2001;44(5):822-33.
2000: Nan Zhang; Biqi Wu; Dennis Powell; Allan Wissner; M Brawner Floyd; ED Kovacs; L Toral-Barza; Constance Kohler
Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.
Bioorganic & medicinal chemistry letters 2000;10(24):2825-8.
2000: Yanong D Wang; K Miller; Diane H Boschelli; Fei Ye; Biqi Wu; M Brawner Floyd; Dennis W Powell; Allan Wissner; JM Weber; Frank Boschelli
Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines.
Bioorganic & medicinal chemistry letters 2000;10(21):2477-80.
2000: C J Torrance; P E Jackson; Elizabeth Montgomery; Kenneth W Kinzler; Bert Vogelstein; Allan Wissner; M Nunes; P Frost; Carolyn Discafani
Combinatorial chemoprevention of intestinal neoplasia.
Nature medicine 2000;6(9):1024-8.
2000: Allan Wissner; D M Berger; Diane H Boschelli; M Brawner Floyd; Lee M Greenberger; Brian C Gruber; Bernard D Johnson; Nellie Mamuya; Ramaswamy Nilakantan; Marvin F Reich; Ru Shen; Hwei-Ru Tsou; E Upeslacis; Yu-Fen Wang; Biqi Wu; Fei Ye; Nan Zhang
4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
Journal of medicinal chemistry 2000;43(17):3244-56.
1999: Carolyn Discafani; M L Carroll; M Brawner Floyd; Irwin Hollander; Zaheed Husain; B D Johnson; D Kitchen; Michael K May; M S Malo; Albert A Minnick; Ramaswamy Nilakantan; Ru Shen; Yu-Fen Wang; Allan Wissner; Lee M Greenberger
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
Biochemical pharmacology 1999;57(8):917-25.